Effects of alendronate on cytokine production and osteoclast formation induced by human marrow stromal cells

J. Moore, J. A. Anderson, G. David Roodman, S. V. Reddy

Research output: Contribution to journalArticle

Abstract

Alendronate is an amino bisphosphate that has recently been approved for treatment of both osteoporosis and Paget's disease of bone due to its potency to inhibit osteoclastic bone resorption. We tested the effects of alendronate on osteoclast formation induced by the marrow stromal cells and on cytokine production in human bone marrow cultures. We recently immortalized a human marrow stromal cell line (Saka) that supports osteoclast formation in vitro and have shown that Saka cells mediate their effects by production of interleukin-1 and interleukin-6, as well as membrane-bound factor. We have also developed a marrow stromal cell line from an affected bone from a patient with Paget's disease and shown that it also enhances osteoclast formation, but does not require cell-to-cell contact for its effects. It also produces stem cell factor, leukemia inhibitory factor, factors not produced by Saka cells, as well as interleukin-1, interleukin-6 and high concentrations of granulocyte macrophage colony-stimulating factor. First, we studied the effect of alendronate on osteoclast-like cell formation in long-term human marrow cultures at various concentrations ranging from 10-5 M to 10-9 M. Alendronate significantly inhibited osteoclast-like cell formation in the presence of 10-8 M 1,25-dihydroxyvitamin D3 at 10-9 M concentration in long-term marrow cultures. However, there was no significant inhibition of osteoclast formation by alendronate at concentrations ranging from 10-6 M to 10-7 M, suggesting a biphasic effect of this compound on osteoclast-like cell formation in human bone marrow cultures. These results were seen in multiple experiments. Further experiments to understand this biphasic effect of alendronate on stromal cell mediated osteoclast formation in human bone marrow cultures are currently ongoing.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume47
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Alendronate
Osteoclasts
Stromal Cells
Bone Marrow
Cytokines
Bone
Interleukin-1
Interleukin-6
Cells
Osteitis Deformans
Leukemia Inhibitory Factor
Cell Line
Stem Cell Factor
Calcitriol
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Resorption
Cell culture
Osteoporosis
Experiments
Membranes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effects of alendronate on cytokine production and osteoclast formation induced by human marrow stromal cells. / Moore, J.; Anderson, J. A.; Roodman, G. David; Reddy, S. V.

In: Journal of Investigative Medicine, Vol. 47, No. 2, 02.1999.

Research output: Contribution to journalArticle

@article{1f96d0b5bf8c4bda97dbedc8d6cc7f89,
title = "Effects of alendronate on cytokine production and osteoclast formation induced by human marrow stromal cells",
abstract = "Alendronate is an amino bisphosphate that has recently been approved for treatment of both osteoporosis and Paget's disease of bone due to its potency to inhibit osteoclastic bone resorption. We tested the effects of alendronate on osteoclast formation induced by the marrow stromal cells and on cytokine production in human bone marrow cultures. We recently immortalized a human marrow stromal cell line (Saka) that supports osteoclast formation in vitro and have shown that Saka cells mediate their effects by production of interleukin-1 and interleukin-6, as well as membrane-bound factor. We have also developed a marrow stromal cell line from an affected bone from a patient with Paget's disease and shown that it also enhances osteoclast formation, but does not require cell-to-cell contact for its effects. It also produces stem cell factor, leukemia inhibitory factor, factors not produced by Saka cells, as well as interleukin-1, interleukin-6 and high concentrations of granulocyte macrophage colony-stimulating factor. First, we studied the effect of alendronate on osteoclast-like cell formation in long-term human marrow cultures at various concentrations ranging from 10-5 M to 10-9 M. Alendronate significantly inhibited osteoclast-like cell formation in the presence of 10-8 M 1,25-dihydroxyvitamin D3 at 10-9 M concentration in long-term marrow cultures. However, there was no significant inhibition of osteoclast formation by alendronate at concentrations ranging from 10-6 M to 10-7 M, suggesting a biphasic effect of this compound on osteoclast-like cell formation in human bone marrow cultures. These results were seen in multiple experiments. Further experiments to understand this biphasic effect of alendronate on stromal cell mediated osteoclast formation in human bone marrow cultures are currently ongoing.",
author = "J. Moore and Anderson, {J. A.} and Roodman, {G. David} and Reddy, {S. V.}",
year = "1999",
month = "2",
language = "English (US)",
volume = "47",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of alendronate on cytokine production and osteoclast formation induced by human marrow stromal cells

AU - Moore, J.

AU - Anderson, J. A.

AU - Roodman, G. David

AU - Reddy, S. V.

PY - 1999/2

Y1 - 1999/2

N2 - Alendronate is an amino bisphosphate that has recently been approved for treatment of both osteoporosis and Paget's disease of bone due to its potency to inhibit osteoclastic bone resorption. We tested the effects of alendronate on osteoclast formation induced by the marrow stromal cells and on cytokine production in human bone marrow cultures. We recently immortalized a human marrow stromal cell line (Saka) that supports osteoclast formation in vitro and have shown that Saka cells mediate their effects by production of interleukin-1 and interleukin-6, as well as membrane-bound factor. We have also developed a marrow stromal cell line from an affected bone from a patient with Paget's disease and shown that it also enhances osteoclast formation, but does not require cell-to-cell contact for its effects. It also produces stem cell factor, leukemia inhibitory factor, factors not produced by Saka cells, as well as interleukin-1, interleukin-6 and high concentrations of granulocyte macrophage colony-stimulating factor. First, we studied the effect of alendronate on osteoclast-like cell formation in long-term human marrow cultures at various concentrations ranging from 10-5 M to 10-9 M. Alendronate significantly inhibited osteoclast-like cell formation in the presence of 10-8 M 1,25-dihydroxyvitamin D3 at 10-9 M concentration in long-term marrow cultures. However, there was no significant inhibition of osteoclast formation by alendronate at concentrations ranging from 10-6 M to 10-7 M, suggesting a biphasic effect of this compound on osteoclast-like cell formation in human bone marrow cultures. These results were seen in multiple experiments. Further experiments to understand this biphasic effect of alendronate on stromal cell mediated osteoclast formation in human bone marrow cultures are currently ongoing.

AB - Alendronate is an amino bisphosphate that has recently been approved for treatment of both osteoporosis and Paget's disease of bone due to its potency to inhibit osteoclastic bone resorption. We tested the effects of alendronate on osteoclast formation induced by the marrow stromal cells and on cytokine production in human bone marrow cultures. We recently immortalized a human marrow stromal cell line (Saka) that supports osteoclast formation in vitro and have shown that Saka cells mediate their effects by production of interleukin-1 and interleukin-6, as well as membrane-bound factor. We have also developed a marrow stromal cell line from an affected bone from a patient with Paget's disease and shown that it also enhances osteoclast formation, but does not require cell-to-cell contact for its effects. It also produces stem cell factor, leukemia inhibitory factor, factors not produced by Saka cells, as well as interleukin-1, interleukin-6 and high concentrations of granulocyte macrophage colony-stimulating factor. First, we studied the effect of alendronate on osteoclast-like cell formation in long-term human marrow cultures at various concentrations ranging from 10-5 M to 10-9 M. Alendronate significantly inhibited osteoclast-like cell formation in the presence of 10-8 M 1,25-dihydroxyvitamin D3 at 10-9 M concentration in long-term marrow cultures. However, there was no significant inhibition of osteoclast formation by alendronate at concentrations ranging from 10-6 M to 10-7 M, suggesting a biphasic effect of this compound on osteoclast-like cell formation in human bone marrow cultures. These results were seen in multiple experiments. Further experiments to understand this biphasic effect of alendronate on stromal cell mediated osteoclast formation in human bone marrow cultures are currently ongoing.

UR - http://www.scopus.com/inward/record.url?scp=33750099323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750099323&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750099323

VL - 47

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -